Stock Detail
HALOZYME THERAPEUTICS INC
Sector: Biotechnology
Latest Quote @ Wed Jun 6 16:15:41 (15 min delayed)
| $6.32 |
$6.40 |
$6.32 |
-0.085 |
-1.33% |
|
Last Day's Data
| $6.41 |
$6.63 |
$0.19 |
3.05% |
0.00 |
$6.22 |
| $6.32 |
$6.32 |
1.00 |
722.41M |
1.34M |
0.00 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 6.76 |
6.58 |
6.45 |
6.27 |
6.14 |
Stock Profile
Halozyme Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of products based on the extracellular matrix for the drug delivery, oncology, and dermatology markets. The company's portfolio of products is based on intellectual property covering the family of human enzymes known as hyaluronidases. Its Enhanze Technology is a novel drug delivery platform, which is designed to increase the absorption and dispersion of biologics. The company has partnership with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets. In addition, Halozyme holds Food and Drug Administration approval for two products: Cumulase and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. The company has partnership with Baxter Healthcare Corporation for HYLENEX. Halozyme also develops various enzymes. The company was founded in 1998 and is based in San Diego, California.
